These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27140804)

  • 1. Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
    Shafer F; Charnigo RJ; Plotka A; Baumann J; Liang Y; Korth-Bradley J
    Clin Pharmacol Drug Dev; 2015; 4(3):237-41. PubMed ID: 27140804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
    Korth-Bradley J; Rupon J; Plotka A; Charnigo R; Rendo P
    Clin Transl Sci; 2018 May; 11(3):283-288. PubMed ID: 29575770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
    Lunghi B; Bernardi F; Martinelli N; Frusconi S; Branchini A; Linari S; Marchetti G; Castaman G; Morfini M
    J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
    Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
    Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
    J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-life extended factor VIII for the treatment of hemophilia A.
    Tiede A
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
    van Moort I; Bukkems LH; Heijdra JM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Ypma P; de Maat MPM; Leebeek FWG; Meijer K; Eikenboom J; Mathôt RAA; Cnossen MH;
    Thromb Haemost; 2020 Jul; 120(7):1056-1065. PubMed ID: 32480417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
    Kessler CM; Gill JC; White GC; Shapiro A; Arkin S; Roth DA; Meng X; Lusher JM
    Haemophilia; 2005 Mar; 11(2):84-91. PubMed ID: 15810908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.